SARASOTA, Fla., Feb. 8, 2018 /PRNewswire/ -- Lakewood-Amedex, Inc., a leading developer of novel anti-infective pharmaceuticals,today announced that it will present at the 2018 BIO CEO & Investor Conference, held February 12-13, 2018, in New York City.
Steve Parkinson, President
Lakewood-Amedex Presentation Details:Date: Tuesday, February 13, 2018 Time: 9:45 AM (Eastern Time)Location: New York Marriott Marquis, Gilbert Room
An audio webcast will be accessible for 90 days following the presentation via the following link: http://www.veracast.com/webcasts/bio/ceoinvestor2018/58208329358.cfm
About Lakewood-Amedex, Inc.Lakewood-Amedex is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The Company's products and technology are covered by an extensive patent portfolio consisting of over 100 granted and/or issued patents and 4 pending patent applications covering many major pharmaceutical markets. The Company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and has recently completed a Phase 1/2a clinical trial in patients with infected diabetic foot ulcers (iDFU).
Contacts:Tiberend Strategic Advisors, Inc.Jonathon Brzezinski, Ph.D. (investors)firstname.lastname@example.org (212) 375-2681
Tiberend Strategic Advisors, Inc.David Schemelia (media)email@example.com (212) 375-2686
View original content:http://www.prnewswire.com/news-releases/lakewood-amedex-inc-to-present-at-2018-bio-ceo--investor-conference-300595543.html
SOURCE Lakewood-Amedex, Inc.
Subscribe to our Free Newsletters!
A patient's struggle with Issacs' syndrome with no cure. Also known as neuromyotonia it is a rare ...
Inguinal hernia surgery is a procedure to repair a weak spot or defect in the lower wall of the ...
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...View All